The anti-VEGF market's impressive Anti Vegf market growth is propelled by several key factors. At the forefront is the global demographic shift, particularly the rapidly expanding geriatric population. Since conditions like AMD and diabetic retinopathy are more prevalent in older individuals, the aging population serves as a primary driver for market expansion. Additionally, the increasing incidence of chronic diseases like diabetes, which leads to vision-threatening complications, further fuels the demand for effective anti-VEGF treatments.

Another significant growth driver is the continuous innovation in drug development. Companies are not only creating novel molecules but also focusing on improved drug delivery systems, such as sustained-release implants, which can reduce the frequency of injections and improve patient adherence and quality of life. This technological progress, combined with supportive regulatory policies and a growing awareness of eye health, creates a fertile ground for market growth. The market's potential for expansion remains high as it addresses a critical health need with significant economic and social implications.